

Oral Abstract Presentation Session I

- Chairs: William Mason *Fox Chase Cancer Center, USA*
Stanley Lemon *University of Texas Medical Branch at Galveston, USA*
- 11:15 Production of infectious genotype 1a (Hutchinson Strain) hepatitis C virus in cultured human hepatoma cells 008
Minkyung Yi *University of Texas Medical Branch at Galveston, USA*
- 11:25 Host-specific response to HCV infection in the chimeric SCID/Alb-uPA mouse model: role of innate antiviral immune response 015
Kathie Walters *University of Washington, USA*
- 11:35 Characterization of SCID/bg Alb-uPA transgenic human chimeric mice infected with either full-length positive strand RNA from hepatitis C virus, or virus derived from tissue culture 016
Michael Joyce *University of Alberta, Canada*
- 11:45 International consensus proposals for the nomenclature and numbering of HCV: creation of a unified system for assignment and database access 017
Carla Kuiken *Los Alamos Hepatitis C Database, USA*
- 12:00 **Lunch Break**

MONDAY EVENING SESSION**The Business of Antiviral Agents**

- Chairs: Denise Pollard-Knight *Nomura Phase4 Ventures, UK*
Kris Thiessen *Helix Management, USA*

17:00 The Business of Antiviral Agents Symposium

Panelists include:

- Frank Zavrl *Equity Analyst, Adage Capital*
Denise Pollard-Knight, PhD *Head of Nomura Phase4 Ventures*
Steven Harr, MD *Executive Director, Morgan Stanley*
Richard Smith, PhD *Research Analyst, JP Morgan Securities, Inc.*
Carol Brosgart, MD *Vice President, Public Health and Policy, Gilead Sciences*
Jean-Pierre Sommadossi, PhD *Founder, CEO and Chairman, Idenix Pharmaceuticals*

Tuesday, December 13, 2005**MORNING SESSION****Next Generation of HBV/HCV Inhibitors**

- Chairs: Yves Benhamou *Hôpital Pitié-Salpêtrière, France*
Robert Gish *California Pacific Medical Center, USA*
- 8:00 VX-950, a novel hepatitis C protease inhibitor
Ann Kwong *Vertex Pharmaceuticals, Inc., USA*
- 8:20 Progress with the clinical development of valopicitabine (NM283) in combination with peg-interferon for the treatment of chronic hepatitis C, in treatment-naïve patients and in non-responders to peg-interferon/ribavirin 021
Christopher O'Brien *University of Miami, USA*
- 8:40 SCH503034: A novel oral HCV protease inhibitor
Eugene Schiff *University of Miami, USA*
- 9:00 Novel potent inhibitors of the HCV NS3/4 protease 022
Lawrence Blatt *InterMune, Inc, USA*

		<u>Abstract</u>
9:20	Interference with HBV receptor interaction by acylated preS-peptides as a novel therapeutic concept for acute and chronic hepatitis B Stephan Urban <i>Ruprecht-Karls-Universität Heidelberg, Germany</i>	023
9:40	Development of a novel mouse model to evaluate drug candidates against wild type and mutant hepatitis B virus Mark Feitelson <i>Thomas Jefferson University, USA</i>	024
10:00	Panel Discussion	
10:30	Break	
Oral Abstract Presentation Session II		
Chairs:	Marion Peters <i>University of California, San Francisco, USA</i> Baruch Blumberg <i>Fox Chase Cancer Center, USA</i>	
11:00	Selective excision of chain-terminating nucleotides by the HCV-associated polymerase Matthias Götte <i>McGill University, Canada</i>	025
11:10	A novel, potent and drug-like class of inhibitors of HCV NS5b viral polymerase John Lambert <i>Biota Holdings Limited, Australia</i>	026
11:20	A Phase 2 study of albuferon plus ribavirin in non-responders to prior interferon based therapy for chronic hepatitis C Vijayan Balan <i>Mayo Clinic, USA</i>	027
11:30	Characterization of the development candidate acyl pyrrolidine 3082 from a novel series of potent HCV polymerase inhibitors Pia Thommes <i>GlaxoSmithKline, UK</i>	028
11:40	Synthesis and antiviral evaluation of hexadecyloxypropyl-(S)-HPMPA against HBV and drug resistant HBV variants, <i>in vitro</i> Karl Hostetler <i>University of California San Diego, USA</i>	029
11:50	Antiviral activity of pradefovir mesylate in patients with lamivudine-resistant HBV infection: 24-week interim analysis from a Phase 2 study Wan-Long Chuang <i>Kaohsiung Medical University Hospital, Taiwan</i>	030
12:00	Lunch Break	
TUESDAY AFTERNOON SESSION		
HEPATITIS B FOUNDATION SYMPOSIUM		
Therapy for Hepatocellular Carcinoma: Current State and Future Prospects		
Chairs:	Timothy Block <i>Drexel Medical College & Hepatitis B Foundation, USA</i> W. Thomas London <i>Fox Chase Cancer Center, USA</i>	
14:00	Introduction Timothy Block <i>Drexel Medical College & Hepatitis B Foundation, USA</i>	
14:05	Current therapies and needs Eddie Cheung <i>University of California, Davis, USA</i>	
14:25	HCC: future therapies Robert Gish <i>California Pacific Medical Center, USA</i>	041
Innovative Horizon Lecture		
14:45	Complex interactions of HBV and its hosts: alterations of human gender ratio Baruch Blumberg <i>Fox Chase Cancer Center, USA</i>	042
15:05	Panel Discussion	

TUESDAY EVENING SESSION

16:30 Poster Reception

Immunology & Vaccine Development

Chairs: Michael Fried *University of North Carolina at Chapel Hill, USA*
 Dennis Liotta *Emory University, USA*

- 18:00 Role of neutralizing antibodies in hepatitis C 043
 Jens Bukh *National Institutes of Health, USA*
- 18:20 Hopes and beyond in the development of vaccines against hepatitis C virus 044
 Geneviève Inchauspé *Transgene, France*
- 18:40 Prophylactic and therapeutic vaccines for HCV
 Amy Weiner *Chiron Corporation, USA*

Oral Abstract Presentation

- 19:00-19:10 T cell-based vaccination protects chimpanzees from chronic infection induced by heterologous HCV challenge 045
 Antonella Folgori *Istituto di Ricerche di Biologia Molecolare (IRBM) "P. Angeletti", Italy*

Wednesday, December 14, 2005

MORNING SESSION

New Therapeutic Approaches and Emerging Targets

Chairs: Thierry Poynard *Hôpital Pitié-Salpêtrière, France*
 Stanley Lemon *University of Texas Medical Branch at Galveston, USA*

- 8:00 The druggable human genome: a long-term view to antiviral agents 049
 Aled Edwards *University of Toronto, Canada*
- 8:20 The toll road to therapy 050
 Devron Averett *Anadys Pharmaceuticals, Inc, USA*
- 8:40 Viral and therapeutic control of host defense against hepatitis C virus 051
 Michael Gale Jr. *University of Texas Southwestern Medical Center, USA*
- 9:00 From bedside to bench to computer to cure: story of hepatitis C virus 052
 Michael Katze *University of Washington, USA*
- 9:20 Regulation of toll-like receptor expression in chronic hepatitis B: role of the precore protein in immunoevasion and pathogenesis 053
 Stephen Locarnini *Victorian Infectious Diseases Reference Laboratory and University of Melbourne, Australia*

Oral Abstract Presentation

- 9:40 Progress in the development of therapeutic siRNAs for the treatment of viral hepatitis 054
 David Morrissey *Sirna Therapeutics, Inc., USA*
- 9:50 Panel Discussion
- 10:10 Break

Hepatocellular Carcinoma and Fibrosis

- Chairs: Eugene Schiff *University of Miami, USA*
 Kris Krawczynski *Centers for Disease Control and Prevention, USA*
- 10:40 Viral hepatitis: a different approach to therapy and iconoclastic view 059
 David Shapiro *Integrated Quality Resources, USA*
- 11:00 Biomarkers for liver fibrosis, steatosis and steatohepatitis 060
 Thierry Poynard *Hôpital Pitié-Salpêtrière, France*
- 11:20 Primary and secondary prevention of HCC epidemics in Japan 061
 Masao Omata *University of Tokyo, Japan*
- 11:40 Panel Discussion

WEDNESDAY EVENING SESSION**Resistance to Antiviral Agents**

- Chairs: Stephen Locarnini *Victorian Infectious Diseases Reference Lab, and
 University of Melbourne, Australia*
 Brent Korba *Georgetown University School of Medicine, USA*
- 16:00 Hepatitis B virus drug resistance: examination of a complex evolution of antiviral 071
 resistance mutations
 Angeline Bartholomeusz *Victorian Infectious Diseases Reference Lab, Australia*
- 16:20 Possible roles of virus replication rates, hepatocyte death rates, 072
 trans-complementation and super-infection in the emergence of drug resistant
 virus strains: theoretical considerations
 William Mason *Fox Chase Cancer Center, USA*
- 16:40 Antiviral/HBIG resistant HBV: impact on transplant practice 073
 Anna Lok *University of Michigan Medical Center, USA*
- 17:00 Infectivity and pathogenicity of monoclonal HBV mutants in chimpanzees 074
 Kris Krawczynski *Centers for Disease Control and Prevention, USA*
- 17:20 Hepatitis C virus drug resistance: the impact of *in vitro* studies on the development 075
 of novel antiviral agents targeting viral or host factors
 Raffaele De Francesco *Istituto di Ricerche di Biologia Molecolare (IRBM)
 "P Angeletti", Italy*

Oral Abstract Presentation

- 17:40 Relationship of amino acid substitutions in the hepatitis B virus reverse transcriptase 076
 that confer entecavir resistance and viral replicative capacity
 Daniel Tenney *Bristol-Myers Squibb, USA*
- 17:50 Panel Discussion
- 18:10 **Break**

Co-Infection with HIV and Other Viruses

- Chairs: Carol Brosgart *Gilead Sciences, USA*
 Robert Murphy *Northwestern University, USA*
- 18:20 HIV HCV management 083
 Marion Peters *University of California, San Francisco, USA*
- 18:40 When and how to treat HIV/HBV coinfection 084
 Bruce Polsky *St. Luke's-Roosevelt Hospital Center, USA*
- 19:00 Safety of anti-HCV and HBV therapy in the HIV-infected patient 082
 Mark Sulkowski *Johns Hopkins University, USA*
- 20:00 **Gala Party**

Thursday, December 15, 2005**MORNING SESSION****Optimizing Outcome of Therapeutics for Hepatitis Infections**

Chairs: Anna Lok *University of Michigan Medical Center, USA*
 Nathaniel Brown *Idenix Pharmaceuticals, USA*

State of the Art Lecture

7:30 When to start, when to stop and when to change
 Yves Benhamou *Hôpital Pitié-Salpêtrière, France*

Treatment for HBV

8:00 Hepatitis B treatment: 2005 and beyond: an overview 092
 Robert Gish *California Pacific Medical Center, USA*

8:20 Entecavir - update on antiviral efficacy and resistance at year two 093
 Richard Colonna *Bristol-Myers Squibb Pharmaceutical Research Institute, USA*

8:40 Significant and sustained clinical improvement following long term treatment with adefovir dipivoxil: results after 5 years of therapy 094
 Carol Brosgart *Gilead Sciences, USA*

9:00 A Phase III comparative trial of telbivudine (LdT) vs. lamivudine for chronic hepatitis B: first-year results from the large international GLOBE trial 095
 Ching-Lung Lai *Queen Mary Hospital, China*

9:20 Proof of concept: pradeфовir is a liver-targeting antiviral with potent activity against HBV 096
 Zhi Hong *Valeant Pharmaceuticals International, USA*

Oral Abstract Presentation

9:40 Maximal HBV suppression in the first six months is associated with optimal virologic and clinical efficacy at one year in nucleoside-treated hepatitis B patients 097
 Adrian DiBisceglie *St. Louis University School of Medicine, USA*

9:50 Panel Discussion

10:05 **Break**

Treatment for HCV

Chairs: Angeline Bartholomeusz *Victorian Infectious Diseases Reference Laboratory, Australia*
 Bruce Polsky *St. Luke's-Roosevelt Hospital Center, USA*

10:20 A genomics approach to the study of chronic hepatitis C virus infection 098
 Ian McGilvray *University of Toronto, Canada*

10:40 Optimizing HCV pharmacodynamics in response to various pegylated interferons: are we there yet? 099
 Avidan Neumann *Bar-Ilan University, Israel*

11:00 Panel Discussion

Closing Session

11:10 Reframing the knowledge at HEP DART 2005
 Eugene Schiff *University of Miami, USA*

12:00 Closing Remarks
 Charles Rice *The Rockefeller University, USA*
 Raymond Schinazi *Emory University/Veterans Affairs Medical Center, USA*